Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings

Pankaj Goyal; Dinesh Chandra Doval; Chaturbhuj Agarwal; Parveen Jain; Krushna Chaudhari; Kshitij Domadia; Pallavi Redhu; Venkata Pradeep Babu Koyyala; Varun Goel; Ullas Batra; Vineet Talwar; Sneha Bothra

doi:10.1055/s-0041-1729726

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(01): 035-045
DOI: 10.1055/s-0041-1729726

Review Article

Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings

Autoren

Pankaj Goyal

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Dinesh Chandra Doval

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Chaturbhuj Agarwal

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Parveen Jain

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Krushna Chaudhari

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Kshitij Domadia

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Pallavi Redhu

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Venkata Pradeep Babu Koyyala

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Varun Goel

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Ullas Batra

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Vineet Talwar

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India
Sneha Bothra

¹Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research, New Delhi, India

Abstract

Breast cancer (BC) is the second most common cancer and the second leading cause of mortality among women globally. Approximately 20 to 25% of BC patients have amplification of the human epidermal growth factor receptor 2 (HER2) genes, a marker of poor prognosis. However, the introduction of anti-HER2-therapies (trastuzumab, followed closely by lapatinib, pertuzumab, trastuzumab emtansine, and neratinib) has changed the natural history of HER2-positive BC and improved the outcome in HER2-positive BC patients. The preeminence of anti-HER2 combination therapy in achieving complete inhibition of the various HER receptor dimers has been demonstrated in clinical studies. However, despite these therapeutic advances, tumors expressing estrogen receptor have poorer responses to targeted therapy and are more likely to relapse. A better understanding of resistance to existing anti-HER2 agents, along with the role played by the microenvironment and of interconnected signaling pathways, can permit tailor-made therapeutic options for each patient. This review aimed to evaluate treatment approaches for BC patients with HER2-positive disease in the adjuvant and neoadjuvant settings, also exploring the possibilities of extended duration of anti-HER2 maintenance therapy.

Keywords

adjuvant - human epidermal growth factor receptor 2 positive breast cancer - neoadjuvant

Volltext

Referenzen

References
1 Cancer Fact Sheet. Available from: https://www.who.int/health-topicscancer#tab=tab_1.Accessed April 1, 2021
2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
3 Breast Cancer. Available from: https://www.who.int/cancer/ prevention/diagnosis-screening/breast-cancer/en/. Accessed April 1, 2021
4 Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 2017; 13 (04) 289-295
5 Mahtani R, Hineman L. Advances in HER2-positive breast cancer: novel therapies and adverse event management. J Adv Pract Oncol 2019; 10 (02) 136-153
6 Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353 (16) 1652-1654
7 Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast 2014; 23 (02) 128-136
8 Baselga J, Coleman RE, Cortés J, Janni W. Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol Hematol 2017; 119: 113-122
9 Zurawska U, Baribeau DA, Giilck S. et al. Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients. Curr Oncol 2013; 20 (06) e539-e545
10 Ahmed S, Sami A, Xiang J. HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer 2015; 22 (02) 101-116
11 Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 2019; 11: 1758835919833519
12 Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart M. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev 2018; 67: 10-20
13 Wuerstlein R, Harbeck N. Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials 2017; 12 (02) 81-92
14 Sharp A, Johnston SR. Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunction. Case Rep Oncol 2015; 8 (01) 113-121
15 Larionov AA. Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol 2018; 8: 89
16 Lv Q, Meng Z, Yu Y. et al. Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer. Int J Mol Sci 2016; 17 (12) 2095
17 Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012; 17 (01) 1-16
18 Meric-Bernstam F, Johnson AM, Dumbrava EE. et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res 2019; 25 (07) 2033-2041
19 Brufsky AM. Current approaches and emerging directions in HER2-resistant breast cancer. Breast Cancer (Auckl) 2014; 8: 109-118
20 Baselga J. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell 2002; 2 (02) 93-95
21 Tzahar E, Waterman H, Chen X. et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16 (10) 5276-5287
22 Lee-Hoeflich ST, Crocker L, Yao E. et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68 (14) 5878-5887
23 Menendez JA, Schroeder B, Peirce SK. et al. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. J Natl Cancer Inst 2015; 107 (06) djv090
24 Franklin MC, Carey KD, Vajdos FF. Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5 (04) 317-328
25 Baselga J, Cortés J, Kim SB. et al. CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366 (02) 109-119
26 Swain SM, Baselga J, Kim SB. et al. CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372 (08) 724-734
27 Baselga J, Bradbury I, Eidtmann H. et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379 (9816) 633-640
28 Blackwell KL, Burstein HJ, Storniolo AM. et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30 (21) 2585-2592
29 Bose R, Kavuri SM, Searleman AC. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3 (02) 224-237
30 Rabindran SK, Discafani CM, Rosfjord EC. et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64 (11) 3958-3965
31 Sánchez-Martín M, Pandiella A. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. Int J Cancer 2012; 131 (01) 244-252
32 Piccart-Gebhart MJ, Procter M, Leyland-Jones B. et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16) 1659-1672
33 Cameron D, Piccart-Gebhart MJ, Gelber RD. et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389 (10075) 1195-1205
34 Perez EA, Romond EH, Suman VJ. et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32 (33) 3744-3752
35 Gianni L, Eiermann W, Semiglazov V. et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 15 (06) 640-647
36 Goss PE, Smith IE, O’Shaughnessy J. et al. TEACH investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14 (01) 88-96
37 Piccart-Gebhart M, Holmes E, Baselga J. et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016; 34 (10) 1034-1042
38 Moreno-Aspitia A, Holmes E, Jackisch C. et al. Updated results from the phase III ALTTO trial (BIG NCCTG/Alliance N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cance. J Clin Oncol 2017; 35: 2-6
39 Chan A, Delaloge S, Holmes FA. et al. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17 (03) 367-377
40 Martin M, Holmes FA, Ejlertsen B. et al. Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2-positive breast cancer: 5-year analysis of the phase III ExteNET trial. Ann Oncol 2017; 28 (Suppl. 05) v43-v67
41 von Minckwitz G, Procter M, de Azambuja E. et al. APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377 (02) 122-131
42 Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014; 57 (16) 6949-6964
43 von Minckwitz G, Huang CS, Mano MS. et al. KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380 (07) 617-628
44 Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008; 34 (06) 539-557
45 Arnould L, Arveux P, Couturier J. et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007; 13 (21) 6404-6409
46 Buzdar AU, Ibrahim NK, Francis D. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23 (16) 3676-3685
47 Gianni L, Eiermann W, Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375 (97/12) 377-384
48 Untch M, Fasching PA, Konecny GE. et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011; 29 (25) 3351-3357
49 Buzdar AU, Suman VJ, Meric-Bernstam F. et al. American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14 (13) 1317-1325
50 Untch M, Rezai M, Loibl S. et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28 (12) 2024-2031
51 Ismael G, Hegg R, Muehlbauer S. et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13 (09) 869-878
52 Untch M, Loibl S, Bischoff J. et al. German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13 (02) 135-144
53 Robidoux A, Tang G, Rastogi P. et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14 (12) 1183-1192
54 Gianni L, Pienkowski T, Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13 (01) 25-32
55 Gianni L, Pienkowski T, Im YH. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17 (06) 791-800
56 Schneeweiss A, Chia S, Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24 (09) 2278-2284
57 Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther 2018; 181: 126-142
58 Verma S, Miles D, Gianni L. et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367 (19) 1783-1791
59 Iwata H, Tamura K, Doi T. et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts. J Clin Oncol 2018; 36: 2501
60 Saura C, Thistlethwaite F, Banerji U. et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer [abstract]. J Clin Oncol 2018; 36: 1014
61 Yurkovetskiy A, Gumerov D, Ter-Ovanesyan E, et al. Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate [abstract]. Proc Am Assoc Cancer Res Annual Meeting 2017. Cancer Res 2017;77 13 Suppl: Abstract nr 48
62 Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C. HER2-positive breast cancer: current and new therapeutic strategies. Breast 2018; 39: 80-88
63 Esposito A, Viale G, Criscitiello C, Curigliano G. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. Expert Rev Clin Pharmacol 2019; 12 (01) 9-16
64 Joensuu H, Bono P, Kataja V. et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27 (34) 5685-5692
65 Slamon D, Eiermann W, Robert N. et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14) 1273-1283
66 Guarneri V, Frassoldati A, Bruzzi P. et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008; 8 (05) 453-456
67 Conte PF, Bisagni G, Frassoldati A. et al. 9 weeks vs. 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian study Short-HER [abstract]. J Clin Oncol 2017; 35: 501
68 Earl HM, Cameron DA, Miles D. et al. The PERSEPHONE trial: duration of trastuzumab with chemotherapy in women with HER-2 positive early breast cancer [abstract]. J Clin Oncol 2012; 30: 660
69 Earl HM, Hiller L, Vallier AL. et al. PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393 (10/191) 2599-2612
70 Tolaney SM, Guo H, Pernas S. et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2019; 37 (22) 1868-1875
71 U.S. Food & Drugs Administration, Prescribing Information for Nerlynx. Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2017/208051s000lbl.pdf. Accessed April 10, 2021.
72 André F, O’Regan R, Ozguroglu M. et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15 (06) 580-591
73 De Laurentiis M, Arpino G, Massarelli E. et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11 (13) 4741-4748
74 Xia W, Bacus S, Hegde P. et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103 (20) 7795-7800
75 Bosch A, Li Z, Bergamaschi A. et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015; 7 (283) 283ra51
76 Johnston S, Pippen J Jr, Pivot X. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27 (33) 5538-5546
77 Kaufman B, Mackey JR, Clemens MR. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27 (33) 5529-5537
78 Rimawi MF, Mayer IA, Forero A. et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013; 31 (14) 1726-1731
79 Nitz UA, Gluz O, Christgen M. et al. West-German Study Group (WSG)-ADAPT Investigators. De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR- phases II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab±weekly paclitaxel. Ann Oncol 2017; 28: 2768-2772